Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoGen has reported total revenue of $5.21m for the third quarter ended 31 March 2011, compared to $3.31m for the same period in 2010.
Subscribe to our email newsletter
For the third quarter ended 31 March 2011, the company’s loss from operations was $15.1m, as compared to $12.22m for the same period last year.
ImmunoGen has posted revenue of $12.8m for the six months ended 31 March 2011, compared to $9.52m for the year ago period.
The company’s loss from operations was $56.79m, compared to $47.42m for the year ago period.
ImmunoGen president and CEO Daniel Junius said their recent achievements underscore their focus on enhancing their development capabilities while maintaining their research strength.
"We’re making solid progress evaluating our IMGN901 compound as part of combination regimens – interim findings from the multiple myeloma trial were accepted for oral presentation at ASCO in June, and we’re on schedule to begin the randomized phase of our small-cell lung cancer trial later this year," Junius said.